ScholarIQanswers from OpenAlex & ORCID
Brian Leyland‐Jones
ResearcherPublications, citations & collaboration network
Brian Leyland‐Jones is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Brian Leyland‐Jones have?
ScholarIQindexed works
Brian Leyland‐Jones has 440 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Brian Leyland‐Jones have?
ScholarIQcitation count
Brian Leyland‐Jones has 32,403 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Brian Leyland‐Jones?
ScholarIQh-index
Brian Leyland‐Jones has an h-index of 65 in OpenAlex.
What is the i10-index of Brian Leyland‐Jones?
ScholarIQi10-index
Brian Leyland‐Jones has an i10-index of 163 in OpenAlex.
What is the ORCID of Brian Leyland‐Jones?
ScholarIQorcid
The ORCID for Brian Leyland‐Jones is on the source record.
What is the OpenAlex record for Brian Leyland‐Jones?
ScholarIQopenalex
The OpenAlex for Brian Leyland‐Jones is on the source record.
What are the most-cited papers on Brian Leyland‐Jones?
ScholarIQmost cited works
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Douglas Yee, Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain, Yunn-Yi Chen, Gregor Krings, Shi Wei, Shuko Harada, Brian Datnow, Oluwole Fadare, Molly Klein, Stefan E. Pambuccian, Beiyun Chen, Kathi Adamson, Sharon B. Sams, Paulette Mhawech‐Fauceglia, Anthony M. Magliocco, Mike Feldman, Mara H. Rendi, Husain Sattar, Jay Zeck, Idris Tolgay Ocal, Ossama Tawfik, Lauren LeBeau, Sunati Sahoo, Tuyethoa N. Vinh, A. Jo Chien, Andres Forero‐Torres, Erica Stringer-Reasor, Anne M. Wallace, Lajos Pusztai, Judy C. Boughey, Erin D. Ellis, Anthony Elias, Janice Lu, Julie E. Lang, Hyo S. Han, Amy S. Clark, Rita Nanda, Donald W. Northfelt, Qamar J. Khan, Rebecca K. Viscusi, David Euhus, Kirsten K. Edmiston, Jane Yuet Ching Hui, Kathleen Kemmer, John W. Park, Minetta C. Liu, Olufunmilayo I. Olopade, Brian Leyland‐Jones, Debasish Tripathy, Stacy L. Moulder, Hope S. Rugo, Richard B. Schwab, Shelly S. Lo, Teresa Helsten, Heather Beckwith, Patricia Haugen, Nola M. Hylton, Laura J. van’t Veer, Jane Perlmutter, Michelle Melisko, Amy Wilson, Garry Peterson, Adam L. Asare, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Jeffrey B. Matthews, Smita Asare, Ashish Sanil, Scott Berry, Laura J. Esserman, Donald A. Berry